NAMS Menopause Certification Exam (MSCP) 2026: Practice Questions & Study Guide | Pass the Menopause Society Certified Practitioner Exam

Are you a licensed healthcare professional ready to demonstrate your expertise in menopause and midlife women's health? The Menopause Society Certified Practitioner (MSCP) credential—formerly known as NCMP—is the definitive certification that validates your mastery of evidence-based menopause care. Administered by The Menopause Society (formerly NAMS), this credential is recognized across North America as the benchmark for excellence in menopause medicine . Why pursue MSCP certification? MSCPs are recognized as the best menopause specialists due to their rigorous training, up-to-date knowledge of hormone therapy and non-hormonal treatment options, and holistic approach to patient care . Certified practitioners report enhanced credibility, increased patient referrals, greater professional recognition, and the personal satisfaction of delivering the highest standard of menopause care . NAMS MENOPAUSE CERTIFICATION EXAM (MSCP) 2026 PRACTICE QUESTIONS WITH VERIFIED ANSWERS & RATIONALES MENOPAUSE SOCIETY CERTIFIED PRACTITIONER TEST BANK Question 1 Continued vasomotor symptoms in a 52-year-old postmenopausal woman with hysterectomy receiving 0.3 mg oral conjugated equine estrogens can best be managed by: Answer: Increasing the daily estrogen dose Rationale: The patient is on the lowest FDA-approved dose of CEE (0.3 mg). With persistent symptoms despite adequate treatment duration (typically 4-8 weeks), dose escalation is appropriate. The 0.3 mg dose may be insufficient for symptom control in some women. Since she had a hysterectomy, no progestogen is needed, simplifying dose adjustment. Question 2 Which agent is best to treat moderate hot flashes in a 55-year-old woman with history of breast cancer? Answer: C. Paroxetine Rationale: • Systemic estrogen is contraindicated in breast cancer survivors • Paroxetine 7.5 mg (Brisdelle) is FDA-approved specifically for VMS • It's a non-hormonal option with demonstrated efficacy • SSRIs/SNRIs are preferred non-hormonal alternatives for breast cancer survivors • Other options like venlafaxine, gabapentin are also used, but paroxetine has FDA approval for this indication Question 3 Which strategy helps reduce VTE risk with HRT? Answer: Use transdermal estrogen instead Rationale: • Transdermal avoids first-pass hepatic metabolism • Lower impact on coagulation factors • Lower VTE risk vs oral estrogen • VTE risk is dose-dependent • Especially important in women with other VTE risk factors Question 4 What is the risk of hormone therapy in women with history of VTE? A) No increased risk B) Increased risk, especially with oral estrogen C) Only increased risk with transdermal D) Risk is eliminated with progestins Correct Answer: B Rationale: Women with a history of VTE have increased risk with hormone therapy, especially with oral estrogen. Transdermal estrogen is preferred if HT is deemed necessary. However, in many cases, HT is contraindicated. Question 5 46-year-old female with pain with intercourse (hysterectomy, ovaries remain), no other menopausal symptoms. Best treatment: Answer: Intravaginal estrogen only Rationale: • Symptoms are localized (no VMS) • Ovaries remain so estrogen production continues • Hysterectomy but ovaries intact = no VMS likely • Intravaginal estrogen targets GSM locally • No progestogen needed (no uterus) Question 6 A 55-year-old woman has been on HT for 10 years and asks about continuing. What is the most appropriate recommendation? A) Continue indefinitely B) Discuss risks/benefits and consider tapering C) Switch to estrogen alone D) Stop immediately due to breast cancer risk Correct Answer: B Rationale: Long-term HT use (5 years) requires ongoing risk-benefit assessment. Shared decision-making about continuation or tapering is essential. Question 7 Best treatment option for 54-year-old postmenopausal woman with vaginal dryness, itching, and dyspareunia (intact uterus): Answer: Intravaginal estrogen cream Rationale: • Local therapy for localized symptoms • Minimal systemic absorption • No endometrial protection needed with low-dose vaginal estrogen • First-line for GSM • Safer than systemic therapy with fewer risks Question 8 What is the "climacteric phase"? A) The final menstrual period B) The period of endocrinologic, somatic, and transitory psychologic changes around the time of menopause C) The perimenopause only D) The postmenopausal period Correct Answer: B Rationale: The climacteric phase is the period of endocrinologic, somatic, and transitory psychologic changes that occur around the time of menopause. It encompasses the transition from the reproductive stage to the non-reproductive stage and includes perimenopause but is not limited to it.